|
"ueno m"的相關文件
顯示項目 1-16 / 16 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2024-12-19 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.]
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 國家衛生研究院 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
|
Chen, LT;Vogel, A;Hsu, C;Chen, MH;Fang, W;Pangarsa, EA;Sharma, A;Ikeda, M;Park, JO;Tan, CK;Regala, E;Tai, D;Tanasanvimon, S;Charoentum, C;Chee, CE;Lui, A;Sow, J;Oh, DY;Ueno, M;Ramaswamy, A;Jeo, WS;Zhou, J;Curigliano, G;Yoshino, T;Bai, LY;Pentheroudakis, G;Chiang, NJ;Cervantes, A;Chen, JS;Ducreux, M |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022 |
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
|
Doki Y.; Ueno M.; CHIH-HUNG HSU; Oh D.-Y.; Park K.; Yamamoto N.; Ioka T.; Hara H.; Hayama M.; Nii M.; Komuro K.; Sugimoto M.; Tahara M. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 國家衛生研究院 |
2020-09 |
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 國家衛生研究院 |
2020-05 |
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 國家衛生研究院 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, LT;Martinelli, E;Cheng, AL;Pentheroudakis, G;Qin, S;Bhattacharyya, GS;Ikeda, M;Lim, HY;Ho, GF;Choo, SP;Ren, Z;Malhotra, H;Ueno, M;Ryoo, BY;Kiang, TC;Tai, D;Vogel, A;Cervantes, A;Lu, SN;Yen, CJ;Huang, YH;Chen, SC;Hsu, C;Shen, YC;Tabernero, J;Yen, Y;Hsu, CH;Yoshino, T;Douillard, JY |
| 臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
| 國立成功大學 |
2020 |
Phase i study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
|
Yoo, C.;Oh, D.-Y.;Choi, H.J.;Kudo, M.;Ueno, M.;Kondo, S.;Chen, L.-T.;Osada, M.;Helwig, C.;Dussault, I.;Ikeda, M. |
| 國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
| 國家衛生研究院 |
2018-11 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 國家衛生研究院 |
2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
|
Yoo, C;Oh, DY;Choi, HJ;Kudo, M;Ueno, M;Kondo, S;Chen, LT;Osada, M;Helwig, C;Dussault, I;Ikeda, M |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
顯示項目 1-16 / 16 (共1頁)
1
每頁顯示[10|25|50]項目
|
